Forecasting the Risk of Adverse Drug Events & Simultaneous Interactions

A Strategic Approach Using Real-world Data and Predict Analytics

Panelists: Sebastian Härtter, PharmD, PhD, Lawrence J. Lesko, PhD, Veronique Michaud, PhD, Jacques Turgeon, PhD

In this open-access educational session, explore how a strategic approach using real-world data and predictive analytics can make pharmacovigilance departments an even more integral part of the drug development process, reducing regulatory and financial risk for pharmaceutical companies.

+ Conceptualize how to conduct adverse drug event (ADE) and simultaneous, multi-drug interaction forecasting for a drug in development, which could improve the drug’s use in different populations based on its pharmacological profile.

+ Understand how to use real-world data and predictive analytics in populations typically excluded from traditional clinical trials.

+ Recognize the risk of medication-related problems for certain patient populations and drug regimens, virtually.

+ Conceptualize an ADE and simultaneous, multi-drug interaction forecast using predictive analytics that helps compare drugs within the same class or with a similar indication.